Prostacyclin Reduces Symptoms and Sympathetic Dysfunction in Erythromelalgia in a Double-blind Randomized Pilot Study

Acta Dermato-Venereologica

Volumn 83, Issue 6, 2003, Pages 442-444

  Kalgaard, Ole M ^a   Mørk, Cato ^a   Kvernebo, Knut ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Clinical trial; Erythromelalgia; Iloprost

Indexed keywords

ILOPROST; PROSTACYCLIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COOLING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; ERYTHEMA; ERYTHROMELALGIA; FEMALE; HEADACHE; HUMAN; HYPOTENSION; INFUSION; INJECTION SITE; ISCHEMIA; LABORATORY TEST; MALE; NAUSEA; NURSE; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN; SYMPATHETIC FUNCTION; VALSALVA MANEUVER; VASOCONSTRICTION;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPOPROSTENOL; ERYTHROMELALGIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; ILOPROST; INFUSIONS, INTRAVENOUS; MALE; PILOT PROJECTS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 0345689648     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/00015550310015031     Document Type: Article

References (21)

1. Thompson GH, Hahn G, Rang M. Erythromelalgia. Clin Orthop 1979; 144: 249-254.
2. Mørk C, Kvernebo K. Erythromelalgia: A mysterious condition? Editorial. Arch Dermatol 2000; 136: 406-409.
3. Smith LA, Allen EV. Erythermalgia (erythromelalgia) of the extremities. A syndrome characterized by redness, heat and pain. Am Heart J 1938; 16: 175-188.
4. Kvernebo K. Erythromelalgia: A condition caused by microvascular arterio-venous shunting. VASA 1998; 51 Suppl: 1-39.
5. Mørk C, Asker CL, Salerud G, Kvernebo K. Microvascular arteriovenous shunting is a probable pathogenetic mechanism in erythromelalgia. J Invest Dermatol 2000; 114: 643-646.
6. Mørk C, Kvernebo K, Asker CL, Salerud EG. Reduced skin capillary density during attacks of erythromelalgia implies arteriovenous shunting as pathogenetic mechanism. J Invest Dermatol 2002; 119: 949-953.
7. Littleford RC, Khan F, Belch JJF. Impaired skin vasomotor reflexes in patients with erythromelalgia. Clin Sci 1999; 96: 507-512.
8. Mørk C, Kvernebo K. Reply. J Invest Dermatol 2000; 115: 1167.
9. Mørk C, Kalgaard OM, Kvernebo K. Impaired neurogenic control of skin perfusion in erythromelalgia. J Invest Dermatol 2002; 118: 699-703.
10. Drenth JPH, Vuzevski V, van Joost T, Casteelsvandaele M, Vermylen J, Michiells JJ. Cutaneous pathology in primary erythromelalgia. Am J Derm 1996; 18: 30-34.
11. Mørk C, Kvernebo K. Erythromelalgia: Therapeutic strategies. In: Lebwohl M, Heymann WR, Berth-Jones J, Coulson I, eds. Treatment of skin disease. Comprehensive therapeutic strategies. Mosby. 2002.
12. Davis MD, Rooke T. Erythromelalgia. Curr Treat Options Cardiovasc Med 2002; 4: 207-222.
13. Cohen JS. Erythromelalgia: New theories and new therapies. J Am Acad Dermatol 2000; 43: 841-847.
14. Belch JJF. Erythromelalgia: A personal perspective. J Dermatol Treat 1992; 3: 153-158.
15. Keller J. Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma. Arch Dermatol Res 1985; 277: 323-325.
16. Yardumaian DA. Successful treatment of Raynaud's syndrome with iloprost: a chemically stable prostacyclin analogue. Br J Rheum 1988; 27: 220-226.
17. Rademaker M, Cooke ED, Almond NE. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomised study. Br Med J 1989; 4: 298.
18. Kalgaard OM, Seem E, Kvernebo K. Erythromelalgia: a clinical study of 87 cases. J Intern Med 1997; 242: 191-197.
19. Jørgensen HP, Søndegaard J. Pathogenesis of erythromelalgia. Arch Dermatol 1978; 114: 112-114.
20. Ozsoylu S, Coskun T. Sodium nitroprusside treatment in erythromelalgia. Eur J Paediatrics 1984; 141: 185-187.
21. The Iloprost Bypass International Study Group. Effects of perioperative iloprost on patency of femorodistal bypass grafts. Eur J Vasc Endovasc Surg 1996; 12: 363-371.